Bladder Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

SITC 2022: Avelumab-Based Combination Therapy for Advanced Urothelial Carcinoma
Risk-Aligned Bladder Cancer Surveillance: Data-Driven Approach to Implementation Mapping
SITC 2022: Phase II Trial Update on Vaccine Plus Pembrolizumab in Resistant Bladder Cancer
ASTRO 2022: Comparison of Trimodal Therapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer
ASTRO 2022: Can Genetic Mutations Determine Response to Trimodality Therapy in Bladder Cancer?
ASTRO 2022: Adding Pelvic Lymph Node Treatment to Bladder-Sparing Chemoradiotherapy for Bladder Cancer
ASTRO 2022: Radiotherapy Versus Surgery for Node-Positive, Nonmetastatic Bladder Cancer
The Role of Memory Immune and Effector Cells in Early Progression of Bladder Cancer
YAP1 Activation: A Potential Prognostic and Therapeutic Factor in Bladder Cancer
A Novel Gene Signature May Help Predict the Prognosis of Bladder Urothelial Carcinoma
Can Photodynamic-Guided Surgery in Non–Muscle-Invasive Bladder Cancer Reduce Recurrences?
Tislelizumab Plus Chemotherapy as First-Line Adjuvant Treatment of Advanced Bladder Cancer
Can Alternative Splicing Help to Reveal a Prognostic Biomarker in Muscle-Invasive Bladder Cancer?
Advanced Urothelial Carcinoma: Combination of Soluble EphB4-Human Serum Albumin Plus Pembrolizumab
Can Response to Palbociclib Therapy for Bladder Tumors Be Predicted by an In Vivo Imaging Biomarker?
ESMO 2022: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer
ESMO 2022: PD-L1 Expression in Dendritic Cells and Survival in Untreated Metastatic Urothelial Cancer
ESMO 2022: Can a Calculated Hypoxia Score Lead to Personalized Treatment in Bladder Cancer?
ESMO 2022: Can MRI-Based Staging of Newly Diagnosed Bladder Cancer Shorten the Time to Appropriate Treatment?
Alternative to Bacillus Calmette-Guérin Under Study in Non-Muscle–Invasive Bladder Cancer
Can Genetic Signatures Predict Tumor Response to Immunotherapy in Bladder Cancer?
Researchers Identify Novel Mechanism in the Proliferation of Bladder Cancer
Is There a Role for Salvage Chemotherapy for Recurrent Bladder Cancer After Radical Cystectomy?
Durvalumab Plus Olaparib in Metastatic Urothelial Carcinoma: Phase II BAYOU Trial
Can ctDNA Status Determine Response to Treatment With Atezolizumab in Bladder Cancer?
FDA Accepts Biologics License Application for Immunotherapy Combination in Bladder Cancer
Bladder Preservation in Geriatric Patients With Muscle-Invasive Bladder Cancer
Do Male Sex Hormones Play a Role in the Higher Rates of Bladder Cancer in Men?
Phase II Study to Assess Bladder-Sparing Combination Therapy for Node–Positive Bladder Cancer
Phase III Trial to Combine Maintenance Avelumab and Cabozantinib in Metastatic Urothelial Cancer
Trimodality Therapy With or Without Adjuvant Durvalumab in Muscle-Invasive Bladder Cancer
Research Sheds Light on Molecular Mechanisms of Cisplatin-Resistant Bladder Cancer
FDA Brief: Fast Track Designation Granted to Belzupacap Sarotalocan in Bladder Cancer
Bladder-Sparing Treatment Under Study in Muscle-Invasive Bladder Cancer With DDR Gene Alterations
The Intersection of Self-Harm, Psychiatric Disorders, and Cancer Diagnoses
Synergistic Effects of APL-1202 Plus Tislelizumab Under Study in Bladder Cancer
ASCO 2022: What Is ‘Platinum Ineligibility’ in Patients With Metastatic Urothelial Cancer?
ASCO 2022: Tislelizumab Plus Nab-Paclitaxel Under Study in Urothelial Bladder Cancer
ASCO 2022: Focus of SWOG S1937 in Metastatic Urothelial Carcinoma Is Eribulin With or Without Gemcitabine
ASCO 2022: COSMIC-021 Cohorts of Cabozantinib Plus Atezolizumab in Urothelial Cancer
ASCO 2022: 2-Year Follow-up on Enfortumab Vedotin for Urothelial Cancer
ASCO 2022: Can N-803 Plus BCG Improve Outcomes in Non–Muscle-Invasive Bladder Cancer?
ASCO 2022: Can Cell-Free DNA Methylation Predict Chemotherapy Benefit in Bladder Cancer?
ASCO 2022: Neoadjuvant Targeting of PD-1 Plus SBRT in Muscle-Invasive Bladder Cancer
ASCO 2022: Neoadjuvant Enfortumab Vedotin-ejfv in Cisplatin-Ineligible Bladder Cancer
Gene-Targeted Therapy for Urothelial Cancer: Study Explores Obstacles to Its Use
Photodynamic Diagnosis May Assist Surgeons With Transurethral Resection of Bladder Cancer


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.